Norethindrone Enanthate

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Norethindrone Enanthate
   1. Pharmacist Assessment Report
   2. Norethindrone Enanthate: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Norethindrone Enanthate: Known uses and market status in Canada

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Norethindrone Enanthate, so there is currently no new predicted indication. No recorded uses are listed for this drug in the data used for this page. The groups below are shown for completeness.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 18 of 18)
Number of DINs	18 (marketed: 18)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02458683	MAEVE		Valid
02441306	JENCYCLA		Valid
00023760	NORLUTATE		Valid
02410303	MOVISSE		Valid
02187108	SYNPHASIC 21 TABLETS		Valid
02189054	BREVICON 1/35 TABLETS (21-DAY PACK)		Valid
02309009	ACTIVELLE LD		Valid
02189062	BREVICON 1/35 TABLETS (28-DAY PACK)		Valid
02199297	SELECT 1/35 (28-DAY)		Valid
02187094	BREVICON 0.5/35 TABLETS (28-DAY PACK)		Valid
02187116	SYNPHASIC 28 TABLETS		Valid
02187086	BREVICON 0.5/35 TABLETS (21-DAY PACK)		Valid
02241837	ESTALIS 250/50 MCG		Valid
02417456	LOLO		Valid
02249405	ACTIVELLE		Valid
02241835	ESTALIS 140/50 MCG		Valid
02197502	SELECT 1/35 (21-DAY)		Valid
02541742	MYFEMBREE		Valid

Safety Considerations

Please refer to the package insert for safety information.

The following should be noted as general considerations from the predicted indications:

• The available cardiovascular literature is old (1969–1992) and addresses lipid effects, including a reduction in HDL with long-term use. It bears on risk assessment, not therapeutic benefit.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---